FDA’s liver safety request set to delay decision on Travere’s kidney drug

The FDA has sunk Travere Therapeutics’ hopes of winning approval for its kidney disease candidate this year by requesting changes to the proposed risk evaluation mitigation strategy (REMS) that are expected to delay the decision date by three months.